<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932280</url>
  </required_header>
  <id_info>
    <org_study_id>16-878</org_study_id>
    <nct_id>NCT02932280</nct_id>
  </id_info>
  <brief_title>Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment</brief_title>
  <official_title>A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arkansas Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of neratinib at different dose levels and to&#xD;
      find out what effects, good and bad, it has on the patients and the cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of patients who have experienced Dose Limiting Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>NCI CTCAE Version 4.0.Definition of Hematologic Dose-Limiting Toxicity (solid tumor cohort only) Any hematologic toxicity as indicated: Febrile neutropenia defined as Grade 3 or 4 neutropenia with fever ≥ 38.5°C and /or infection requiring antibiotic or antifungal treatment Grade 4 neutropenia lasting &gt; 7 days Grade 4 thrombocytopenia lasting &gt; 7days Any drug-related adverse experience, regardless of grade, leading to a dose reduction of a study drug. Non-Hematologic Dose-Limiting Toxicities: Non-hematologic dose-limiting toxicity will be defined as any Grade 3, 4 or 5 nonhematologic toxicity with the specific exception of: Any grade diarrhea that occurs in the setting of poor compliance with supportive measures that last for &lt; 48 hours Any grade dehydration related to diarrhea that occurs in the setting of inadequate compliance to supportive care measures that last for &lt; 48 hours.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Central Nervous System Tumor</condition>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Neratinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neratinib</intervention_name>
    <description>Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).</description>
    <arm_group_label>Neratinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis: Pathologic confirmation of solid tumor, including central nervous system&#xD;
             tumor or lymphoma.&#xD;
&#xD;
          -  Recurrent or Refractory Disease for which no further effective standard treatment is&#xD;
             available.&#xD;
&#xD;
          -  Patient must have failed at least one prior therapy.&#xD;
&#xD;
          -  All patients must have evaluable disease as defined as:&#xD;
&#xD;
               -  Solid tumors must have a lesion evaluable by RECIST criteria version 1.1;&#xD;
&#xD;
               -  Central nervous system tumors will be evaluated by RANO criteria.&#xD;
&#xD;
          -  Available tissue to perform protein and genomic analysis&#xD;
&#xD;
          -  Age:&#xD;
&#xD;
               -  Phase 1: ≥ 3 and ≤ 21 years of age at time of enrollment&#xD;
&#xD;
               -  Phase 2: ≥ 3 and ≤ 21 years of age at diagnosis&#xD;
&#xD;
          -  Body Surface Area requirements varied by dose level:&#xD;
&#xD;
        Dose Level BSA (m2)&#xD;
&#xD;
          -  1 ≥ 0.82&#xD;
&#xD;
               1. ≥ 0.66&#xD;
&#xD;
               2. ≥ 0.52&#xD;
&#xD;
               3. ≥ 0.45&#xD;
&#xD;
          -  Performance level:&#xD;
&#xD;
               -  Lansky score ≥ 60% (patients &lt; 16 years of age)&#xD;
&#xD;
               -  Karnofsky score ≥ 60% (patients ≥ 16 years of age)&#xD;
&#xD;
          -  Cardiac Function: Patients must have a shortening fraction ≥ 27% or left ventricular&#xD;
             ejection fraction ≥ 50% measured by echocardiogram (ECHO) or measured by&#xD;
             multiple-gated acquisition scans (MUGA).&#xD;
&#xD;
          -  Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of&#xD;
             child-bearing potential ≤ 7 days before starting neratinib therapy.&#xD;
&#xD;
          -  Female patients of reproductive potential must agree and commit to the use of a highly&#xD;
             effective method of contraception, as determined to be acceptable by the investigator,&#xD;
             from the time of informed consent until 28 days after the last dose of the&#xD;
             investigational product. Male patients must agree and commit to use a barrier method&#xD;
             of contraception while on treatment and for 3 months after the last dose of the&#xD;
             investigational product.&#xD;
&#xD;
          -  Written informed consent/assent prior to any study-specific procedures.&#xD;
&#xD;
          -  Patient must be able to swallow tablet or have existing gastrostomy feeding tube to&#xD;
             enable administration of tablet.&#xD;
&#xD;
          -  Patients must have recovered from the acute toxic effects of all prior therapy to ≤&#xD;
             grade 1 before entering this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment within the following timeframes:&#xD;
&#xD;
               -  Systemic chemotherapy or biologic therapy ≤ 2 weeks or 5 half lives (t ½) of the&#xD;
                  agent used, whichever is shorter, prior to the start of neratinib&#xD;
&#xD;
               -  Radiation therapy outside the central nervous system ≤ 14 days prior to neratinib&#xD;
&#xD;
               -  Radiation to the central nervous system ≤ 12 weeks prior to initiation of&#xD;
                  neratinib&#xD;
&#xD;
          -  Patients with previous allogeneic stem cell transplant (SCT) if they meet either of&#xD;
             the following criteria:&#xD;
&#xD;
               -  60 days from allogeneic SCT&#xD;
&#xD;
                    -  Active acute or chronic graft-versus-host-disease (GvHD) or receiving&#xD;
                       immunosuppressive therapy as treatment for GvHD&#xD;
&#xD;
          -  Inadequate marrow function in Cohort 1:&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1.0 x 10^9 /L&#xD;
&#xD;
               -  Platelets &lt; 100 x 10^9 /L&#xD;
&#xD;
               -  Hemoglobin &lt; 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 X the upper limit of normal (ULN) for age&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) &gt; 3 X ULN (unless attributed to disease involvement)&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 X ULN for age or creatinine clearance ≤ 60mL/min/1.73m^2&#xD;
&#xD;
          -  Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic&#xD;
             brain disease who have been on a stable dose of corticosteroids for treatment of brain&#xD;
             metastases for at least 14 days (or decreasing dose of corticosteroid) are eligible to&#xD;
             participate in the study.) Patients with primary central nervous system tumors are&#xD;
             eligible.&#xD;
&#xD;
          -  Clinically active cardiac disease, including prolonged QTc interval ≥ 481ms (i.e. ≥&#xD;
             grade 2)&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Being actively treated for a concurrent malignancy with the exception of basal cell&#xD;
             carcinoma or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to uncontrolled&#xD;
             infection, unexplained fever &gt; 38.5°C (101.3°F) or psychiatric illness/social&#xD;
             situation that would limit compliance with study requirements.&#xD;
&#xD;
          -  Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g.,&#xD;
             Crohn's disease, malabsorption, or Grade ≥ 2 National Cancer Institute [NCI] Common&#xD;
             Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any&#xD;
             etiology at baseline).&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection or acquired&#xD;
             immunodeficiency syndrome (AIDS)-related disease&#xD;
&#xD;
          -  Known history of hepatitis C or known active hepatitis B infection&#xD;
&#xD;
          -  Known hypersensitivity to any component of the investigational product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Trippett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanya Trippett, MD</last_name>
    <phone>212-639-8267</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manjusha Namuduri, MD</last_name>
    <phone>212-639-7937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children'S Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Boklan, MD</last_name>
      <phone>602-546-0920</phone>
    </contact>
    <investigator>
      <last_name>Jessica Boklan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Neville, MD, MS</last_name>
      <phone>816-364-4405</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Neville, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine and Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Lacayo, MD</last_name>
      <phone>650-723-5533</phone>
    </contact>
    <investigator>
      <last_name>Norman Lacayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Smith, MD</last_name>
      <phone>321-841-8588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Trippett, MD</last_name>
      <phone>212-639-8267</phone>
    </contact>
    <contact_backup>
      <last_name>Manjusha Namuduri, MD</last_name>
      <phone>212-639-7937</phone>
    </contact_backup>
    <investigator>
      <last_name>Tanya Trippett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State Hershey Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Brown, MD. PhD</last_name>
      <phone>717-531-6012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Langevin, MD</last_name>
      <phone>210-743-2300</phone>
    </contact>
    <investigator>
      <last_name>Anne-Marie Langevin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institue</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luke Maese, DO</last_name>
      <phone>801-213-6226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Children'S Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aru Narendran, MD, PhD</last_name>
      <phone>403.210.6418</phone>
    </contact>
    <investigator>
      <last_name>Aru Narendran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent</keyword>
  <keyword>Refractory Disease</keyword>
  <keyword>Neratinib</keyword>
  <keyword>16-878</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

